{"id":"vancomycin-or-fidaxomicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL262777","moleculeType":"Small molecule","molecularWeight":"1449.27"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, while Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase. Both are used to treat C. difficile-associated diarrhea (CDAD), with Fidaxomicin showing lower recurrence rates due to minimal systemic absorption and targeted local activity in the colon.","oneSentence":"Vancomycin and Fidaxomicin are antibiotics that inhibit bacterial cell wall synthesis or protein synthesis to treat Clostridioides difficile infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:28.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile-associated diarrhea (CDAD)"},{"name":"Recurrent C. difficile infection"}]},"trialDetails":[{"nctId":"NCT06884748","phase":"EARLY_PHASE1","title":"Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-01","conditions":"Clostridioides Difficile Infection","enrollment":30},{"nctId":"NCT05266807","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence","status":"RECRUITING","sponsor":"Benoit Guery","startDate":"2023-03-15","conditions":"Clostridioides Difficile Infection","enrollment":220},{"nctId":"NCT07120490","phase":"NA","title":"STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-10","conditions":"Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT)","enrollment":424},{"nctId":"NCT02218372","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-09","conditions":"Clostridium Difficile-associated Diarrhea (CDAD)","enrollment":148},{"nctId":"NCT05447533","phase":"NA","title":"Clostridioides Difficile and Frailty","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-09-16","conditions":"Frail Elderly, Clostridioides Difficile, Geriatric Assessment","enrollment":217},{"nctId":"NCT03182907","phase":"PHASE3","title":"Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-27","conditions":"Clostridium Difficile Infection","enrollment":148},{"nctId":"NCT05077085","phase":"PHASE4","title":"Bezlotoxumab Versus FMT for Multiple Recurrent CDI","status":"WITHDRAWN","sponsor":"Leiden University Medical Center","startDate":"2022-01","conditions":"Clostridium Infections, Clostridioides Difficile, Enterocolitis, Pseudomembranous","enrollment":""},{"nctId":"NCT04317963","phase":"","title":"Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2020-02-12","conditions":"Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence","enrollment":180},{"nctId":"NCT02692651","phase":"PHASE4","title":"A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-05-01","conditions":"Clostridium Difficile Infection (CDI)","enrollment":144},{"nctId":"NCT02461901","phase":"","title":"Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?","status":"COMPLETED","sponsor":"Professor Mark Wilcox","startDate":"2015-01","conditions":"Clostridium Difficile Infection","enrollment":203},{"nctId":"NCT01241552","phase":"PHASE3","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-10","conditions":"Clostridium Difficile Infection","enrollment":1452},{"nctId":"NCT01513239","phase":"PHASE3","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-01","conditions":"Clostridium Difficile Infection","enrollment":1203},{"nctId":"NCT03053505","phase":"NA","title":"A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection","status":"UNKNOWN","sponsor":"Sejtterapia Kozpont Kft.","startDate":"2017-01","conditions":"Clostridium Difficile Infection","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43175,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vancomycin or Fidaxomicin","genericName":"Vancomycin or Fidaxomicin","companyName":"Sejtterapia Kozpont Kft.","companyId":"sejtterapia-kozpont-kft","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin and Fidaxomicin are antibiotics that inhibit bacterial cell wall synthesis or protein synthesis to treat Clostridioides difficile infections. Used for Clostridioides difficile-associated diarrhea (CDAD), Recurrent C. difficile infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}